Researchers in Japan are developing world-leading expertise in making and using the alpha particle emitter, astatine-211 (211 At), which has potential for use as a strong radionuclide therapy for ...

A newly developed astatine-211 (211At)-labeled peptide drug inhibits malignant melanoma cells by releasing alpha particles in the targeted cancer tissue.

Researchers said alpha particles are promising therapies that target cancer while minimizing the damage to nearby healthy tissues.